VP, GPL Franchise Lead Oncology at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Reports to the SVP, Head of Development, HOCT with matrix reporting to the SVP, Drug Development Strategy & Portfolio Management
Leadership experience to lead and inspire a high-performing organization of Global Program Leaders (GPLs) across the Disease Area
Strategic and technical leadership to build a world-class drug development team, balancing scientific excellence and operational effectiveness
Inspirational leadership to engage, develop, and create an inclusive/diverse environment that drives innovation
Superior enterprise mindset and leadership maturity to shape the future of R&D
Ability to prioritize, synthesize, and pressure test feedback from senior leadership and coach GPLs in building this skillset
Capability to ensure Program Leaders demonstrate must-win capabilities and partner effectively with R&D functions and across the Enterprise
Experience in leveraging expertise to integrate information, facilitate rapid and objective data-driven decisions, and lead team problem-solving

Responsibilities

Develops Disease Area Portfolio Strategy: Set the end-to-end disease strategy spanning the full lifecycle in partnership with drug development functions (including Strategy & Portfolio Management, global regulatory & safety, and global development operations), and other functions (including research, commercialization, GPS, and enterprise strategy)
Accelerate the portfolio and reduce development timelines for most promising new assets, while optimizing the revenue and reach of currently marketed products
Lead all R&D business development activities for the Oncology portfolio, in partnership with the Business Development team and DD Strategy & Portfolio Management
Effectively manage disease portfolio budget, making tradeoff decisions with enterprise mindset
Drives execution of portfolio strategy through leadership of Disease Area Global Program Leads: Lead and inspire a high-performing organization of Global Program Leaders (GPLs) across the Disease Area
Oversee orchestration of design and execution of globally integrated program strategies, timelines, and budgets from candidate nomination to successful launch, commercialization, and lifecycle management within Oncology
Engage senior leaders and functional area stakeholders to ensure alignment of program strategy and operational plans
Clearly communicate program risks, implications of changes in the competitive landscape, and progress toward key milestones
Lead team problem-solving in delivering key data and interpretation essential for robust debate and rapid, data-driven decision making

Skills

Oncology

Portfolio Strategy

Disease Strategy

Drug Development

Global Regulatory

Strategic Planning

Cross-functional Leadership

Team Leadership

Lifecycle Management

Portfolio Optimization

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free